The market has been down on GW Pharmaceuticals PLC- ADR (GWPH) stock recently. GWPH gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With GWPH Stock Today?
GW Pharmaceuticals PLC- ADR (GWPH) stock is lower by -1.31% while the S&P 500 has risen 0.19% as of 2:21 PM on Tuesday, Aug 11. GWPH has fallen -$1.49 from the previous closing price of $113.95 on volume of 220,623 shares. Over the past year the S&P 500 is up 16.46% while GWPH has fallen -29.44%. GWPH lost -$1.79 per share in the over the last 12 months.
More About GW Pharmaceuticals PLC- ADR
GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.